BLCO - Bausch + Lomb Corpo... Stock Analysis | Stock Taper
Logo
Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation NYSE
$18.30 -1.00% (-0.19)

Market Cap $6.48 B
52w High $18.91
52w Low $10.45
P/E -17.94
Volume 231.49K
Outstanding Shares 354.32M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $1.41B $658M $-58M -4.13% $-0.16 $257M
Q3-2025 $1.28B $676M $-28M -2.19% $-0.08 $207M
Q2-2025 $1.28B $764M $-62M -4.85% $-0.18 $88M
Q1-2025 $1.14B $738M $-212M -18.65% $-0.6 $20M
Q4-2024 $1.28B $692M $-3M -0.23% $-0.01 $194M

What's going well?

Revenue is growing strongly, and the core business is becoming more profitable. Operating income jumped 66% from last quarter, showing the company can generate profits before debt and unusual items.

What's concerning?

Net losses are widening due to high interest and significant 'other' expenses. Margins are under pressure, and the company is not yet turning sales growth into bottom-line profits.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $383M $14.02B $7.5B $6.45B
Q3-2025 $310M $13.83B $7.33B $6.43B
Q2-2025 $272M $13.83B $7.32B $6.44B
Q1-2025 $202M $13.43B $7B $6.36B
Q4-2024 $305M $13.47B $6.92B $6.47B

What's financially strong about this company?

Shareholder equity is solid at $6.45 billion, and the company has enough current assets to cover its short-term bills. Most debt is long-term, so there are no big near-term repayment risks.

What are the financial risks or weaknesses?

Cash is low for a company of this size, and over half of assets are intangible (goodwill and intangibles), which could be written down if business slows. Retained earnings are negative, showing a history of losses.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-58M $134.34M $-184.86M $114.8M $65M $61.8M
Q3-2025 $-28M $139.05M $-61.3M $-12.55M $60M $64.53M
Q2-2025 $-58M $35M $-90M $90M $57M $-54M
Q1-2025 $-211M $-25M $-116M $31M $-101M $-135M
Q4-2024 $-2M $22M $-185M $146M $-34M $-70M

What's strong about this company's cash flow?

The business produces strong, consistent cash from its core operations, even while reporting an accounting loss. Free cash flow remains positive after investments, and there's no shareholder dilution.

What are the cash flow concerns?

Cash flow from operations dipped slightly, and the company relied on a large debt raise to increase its cash. Working capital swings, especially rising receivables, hurt cash flow and could signal collection or sales issues.

Revenue by Products

Product Q1-2025Q2-2025Q3-2025Q4-2025
Branded and Other Generic Products
Branded and Other Generic Products
$50.00M $60.00M $60.00M $70.00M
Device Products
Device Products
$450.00M $470.00M $480.00M $520.00M
Other Revenues
Other Revenues
$0 $10.00M $0 $10.00M
Over the Counter Products
Over the Counter Products
$410.00M $480.00M $450.00M $490.00M
Pharmaceutical Products
Pharmaceutical Products
$220.00M $260.00M $280.00M $320.00M

Revenue by Geography

Region Q1-2024Q2-2024Q3-2024Q4-2024
CANADA
CANADA
$30.00M $30.00M $30.00M $30.00M
CHINA
CHINA
$80.00M $90.00M $90.00M $100.00M
FRANCE
FRANCE
$60.00M $60.00M $50.00M $50.00M
GERMANY
GERMANY
$40.00M $40.00M $40.00M $30.00M
ITALY
ITALY
$20.00M $20.00M $20.00M $20.00M
JAPAN
JAPAN
$40.00M $40.00M $40.00M $50.00M
KOREA REPUBLIC OF
KOREA REPUBLIC OF
$10.00M $10.00M $10.00M $0
MEXICO
MEXICO
$20.00M $20.00M $20.00M $20.00M
Other Countries
Other Countries
$170.00M $170.00M $170.00M $240.00M
POLAND
POLAND
$10.00M $20.00M $20.00M $10.00M
SPAIN
SPAIN
$20.00M $30.00M $20.00M $30.00M
United States and Puerto Rico
United States and Puerto Rico
$540.00M $610.00M $610.00M $660.00M

Q4 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Bausch + Lomb Corporation's financial evolution and strategic trajectory over the past five years.

+ Strengths

BLCO combines a globally recognized brand, a broad and integrated portfolio across key eye care segments, and a revitalized innovation pipeline. Revenue growth has been solid and accelerating, supported by differentiated technologies in contact lenses and surgical products and by strategic moves in dry eye and other therapeutic areas. The balance sheet now shows low debt and a net cash position, giving the company more flexibility to weather volatility and continue funding its strategic initiatives. Its long history and deep relationships with eye care professionals provide an intangible advantage that is difficult for newer entrants to replicate.

! Risks

The main risks are financial and competitive. Profitability has deteriorated from modest profits to persistent losses, with negative net margins, shrinking EBITDA, and weak or negative free cash flow over several recent years. Rising operating expenses, investment needs, and prior interest costs have weighed heavily on results, leading to negative retained earnings and a thinner equity cushion. The asset base is heavily skewed toward goodwill and intangibles, which could be vulnerable if business performance does not meet expectations. On top of this, BLCO faces intense competition in every major product category, and its reliance on a limited number of key products creates concentration risk.

Outlook

Looking ahead, BLCO’s prospects hinge on its ability to translate strong revenue momentum and a promising innovation pipeline into sustainable profits and healthier cash flows. The recent deleveraging and solid liquidity put the company in a better position to execute its strategy without the same financial strain as before. If management can improve cost discipline, enhance operating efficiency, and successfully launch and scale upcoming products in contact lenses, dry eye, and myopia control, the long-term opportunity in global eye care is substantial. However, until profitability and free cash flow show consistent and durable improvement, the story will remain a balance between an attractive strategic position and meaningful execution and financial risks.